title: Developing imaging strategies for castration resistant prostate cancer.
abstract: Recent advances in the understanding of castrate-resistant prostate cancer (CRPC) have lead to a growing number of experimental therapies, many of which are directed against the androgen-receptor (AR) signaling axis. These advances generate the need for reliable molecular imaging biomarkers to non-invasively determine efficacy, and to better guide treatment selection of these promising AR-targeted drugs. Methods. We draw on our own experience, supplemented by review of the current literature, to discuss the systematic development of imaging biomarkers for use in the context of CRPC, with a focus on bone scintigraphy, F-18 fluorodeoxyglucose (FDG)-positron emission tomography (PET) and PET imaging of the AR signaling axis. Results. The roadmap to biomarker development mandates rigorous standardization and analytic validation of an assay before it can be qualified successfully for use in an appropriate clinical context. The Prostate Cancer Working Group 2 (PCWG2) criteria for "radiographic" progression by bone scintigraphy serve as a paradigm of this process. Implemented by the Prostate Cancer Clinical Trials Consortium (PCCTC), these consensus criteria may ultimately enable the co-development of more potent and versatile molecular imaging biomarkers. Purported to be superior to single-photon bone scanning, the added value of Na(18)F-PET for imaging of bone metastases is still uncertain. FDG-PET already plays an integral role in the management of many diseases, but requires further evaluation before being qualified in the context of CRPC. PET tracers that probe the AR signaling axis, such as (18)F-FDHT and (89)Zr-591, are now under development as pharmacodynamic markers, and as markers of efficacy, in tandem with FDG-PET. Semi-automated analysis programs for facilitating PET interpretation may serve as a valuable tool to help navigate the biomarker roadmap. Conclusions. Molecular imaging strategies, particularly those that probe the AR signaling axis, have the potential to accelerate drug development in CRPC. The development and use of analytically valid imaging biomarkers will increase the likelihood of clinical qualification, and ultimately lead to improved patient outcomes.
authors: Nuclear Medicine Service, Department of Radiology, Memorial Sloan-Kettering Cancer Center, 1275 York Avenue, New York, NY 10065, USA. foxj@mskcc.org
authors: Josef J
authors: JJ
authors: Fox
authors: Michael J
authors: MJ
authors: Morris
authors: Steven M
authors: SM
authors: Larson
authors: Heiko
authors: H
authors: Schöder
authors: Howard I
authors: HI
authors: Scher
references: Cancer. 2000 Jun 15;88(12 Suppl):2989-94
references: 10898342
references: Radiology. 1996 Jun;199(3):751-6
references: 8638000
references: Hum Pathol. 2000 May;31(5):578-83
references: 10836297
references: J Nucl Med. 2009 May;50 Suppl 1:122S-50S
references: 19403881
references: Science. 2009 May 22;324(5930):1029-33
references: 19460998
references: Clin Positron Imaging. 2000 Jul;3(4):131-136
references: 11150744
references: J Nucl Med. 2010 Feb;51(2):183-92
references: 20080885
references: J Nucl Med. 2006 Feb;47(2):287-97
references: 16455635
references: Clin Positron Imaging. 1999 May;2(3):159-171
references: 14516540
references: Cancer. 1997 Dec 15;80(12 Suppl):2505-9
references: 9406703
references: Nucl Med Biol. 1996 Aug;23(6):693-7
references: 8940712
references: AJR Am J Roentgenol. 1984 Apr;142(4):773-6
references: 6230903
references: Urology. 1996 Aug;48(2):326-34
references: 8753752
references: J Nucl Med. 1962 Jul;3:332-4
references: 13869926
references: Eur J Cancer. 2009 Jan;45(2):228-47
references: 19097774
references: Radiology. 1971 Apr;99(1):192-6
references: 5548678
references: Clin Genitourin Cancer. 2009 Jan;7(1):51-7
references: 19213669
references: Clin Pharmacol Ther. 2001 Mar;69(3):89-95
references: 11240971
references: J Nucl Med. 1992 May;33(5):724-34
references: 1569482
references: Lancet. 2010 Apr 24;375(9724):1437-46
references: 20398925
references: J Nucl Med. 2010 Aug;51(8):1293-300
references: 20660376
references: Toxicology. 2008 Mar 20;245(3):219-23
references: 18280028
references: Radiology. 1983 Feb;146(2):513-8
references: 6294738
references: Proc R Soc Med. 1929 Aug;22(10):1383-6
references: 19987141
references: Clin Cancer Res. 2010 Dec 15;16(24):6093-9
references: 20975102
references: Nat Med. 2004 Jan;10(1):33-9
references: 14702632
references: Prostate Cancer Prostatic Dis. 2009;12(3):241-6
references: 19597531
references: Prostate. 2009 Oct 1;69(14):1579-85
references: 19575420
references: J Clin Oncol. 2010 Mar 20;28(9):1496-501
references: 20159814
references: Clin Cancer Res. 2005 Apr 15;11(8):2785-808
references: 15837727
references: J Nucl Med. 2006 Jun;47(6):901-3
references: 16741296
references: Clin Cancer Res. 2010 Jul 1;16(13):3299-318
references: 20501613
references: Clin Cancer Res. 2005 May 1;11(9):3210-6
references: 15867215
references: Eur J Nucl Med Mol Imaging. 2005 Mar;32(3):344-50
references: 15726353
references: J Nucl Med. 1997 Sep;38(9):1401-6
references: 9293797
references: Urology. 2002 Jun;59(6):913-8
references: 12031380
references: Clin Cancer Res. 1998 Jul;4(7):1765-72
references: 9676853
references: J Nucl Med. 2006 Jun;47(6):1059-66
references: 16741317
references: J Clin Oncol. 2010 Mar 20;28(9):1489-95
references: 20159823
references: J Clin Oncol. 1999 Mar;17(3):948-57
references: 10071289
references: J Natl Cancer Inst. 2009 Feb 18;101(4):216-7
references: 19211455
references: J Nucl Med. 2009 Mar;50(3):368-75
references: 19223423
references: J Clin Oncol. 2008 Mar 1;26(7):1148-59
references: 18309951
references: Cancer. 2003 Feb 1;97(3 Suppl):758-71
references: 12548573
references: J Nucl Med. 2004 Mar;45(3):366-73
references: 15001675
references: J Natl Cancer Inst. 2000 Feb 2;92(3):205-16
references: 10655437
references: J Nucl Med. 2008 Jul;49(7):1066-74
references: 18552139
references: Urology. 2000 Mar;55(3):323-7
references: 10699601
references: J Nucl Med. 2008 Dec;49(12):2031-41
references: 18997047
references: J Nucl Med. 2008 Dec;49(12):1958-65
references: 18997038
references: Nat Rev Cancer. 2001 Oct;1(1):34-45
references: 11900250
references: Curr Opin Pharmacol. 2008 Aug;8(4):440-8
references: 18674639
references: Clin Cancer Res. 2005 Jul 15;11(14):5223-32
references: 16033840
references: Clin Pharmacol Ther. 2007 Jan;81(1):104-7
references: 17186007
references: J Cancer. 2010 Jun 28;1:80-92
references: 20842228